Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cellceutix (CTIX.OB) Closing in on Bringing Kevetrin to Human Trials for Multi-Drug Resistant Cancers

Cellceutix Corporation (OTCBB: CTIX) announced today that they have received nearly all the data regarding the toxicology studies for Kevetrin, the Company’s flagship compound for the treatment of multi drug-resistant cancers.  The remaining data is expected within two or three weeks.  This data is the final information required for the Investigational New Drug Application (NYSE:IND) to be prepared and submitted to the U.S. Food and Drug Administration.  In preparation for the filing, Cellceutix has engaged additional consultation to bring Kevetrin to human trials. 


George Evans, CEO of Cellceutix, commented, "We are continuing to hit our targets at or ahead of schedule with Kevetrin. The pre-clinical data to date has been extremely encouraging and we expect that these final data are going to fall right into line." Mr. Evans continued, "We are well aware of the significant impact Kevetrin can provide to patients in need if Kevetrin can perform in human trials as it has in the pre-clinical research. We are presently organizing the team for the IND and doing all possible preparation in order to submit the filing quickly once the final toxicology data is in our hands."

"I have been closely involved in the development of several successful compounds in my 30 years in the industry and am extremely encouraged by the data that Kevetrin has produced," stated Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. "The completion of pre-clinical studies creates a great deal of excitement for our team as we are anxious to see Kevetrin being utilized as a human therapy in the near future."

It is interesting to note that Dr. Menon makes the comment about developing successful compounds in the past.  In a recent interview on, Leo Ehrlich, CFO of Cellceutix is quoted as saying, “Our chief scientific officer, who developed our cancer drug, was a group leader of cancer research at Eli Lilly (NYSE: LLY). He was the key developer of two blockbuster cancer drugs named Alimta and Gemzar, which generate billions of dollars in sales.”  The history of CEO George Evans and his extensive experience as General Counsel at Pfizer coupled with the experiences of Dr. Menon and the rest of the Advisory Board (which can be viewed at should make many industry-leaders take notice of Cellceutix. 

The pre-clinical research of Kevetrin appears to have moved smoothly and quickly with a lot of extremely promising data.  In the biotechnology world, companies are VERY careful not to divulge too much information or makes statements that can be misleading as there is always a possibility that drugs will fail as research and testing continues.  This makes complete sense from every legal aspect.  But, it should not go without recognition that the team at Cellceutix has a very distinguished history.  It may be worth a much closer look.

More due diligence on Cellceutix Corporation, the compounds in the pipeline and the investment opportunity presented can be found on the Company’s website at 


OTC Showcase is in the business of providing corporate information to create market and public awareness for publicly traded companies and do so through our website and affiliates.  In some cases, OTC Showcase has been compensated to provide the information to the public.  In some cases, the information is provided to us and we do all that we can to ensure the accuracy of the information, but cannot guarantee all information to be accurate. Information in our emails, press releases, message board postings and on our Web site may contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934 and must be realized as such.  We are not licensed financial advisors in any way, shape or form and none of the information provided should be used as investment advice.  Always consult a qualified and licensed financial advisor before making any investment as investing and trading can contain high elements of risk in which you may lose some or all of your money.  OTC Showcase always intends to remain 100% compliant with Section 17(b) of the Security Act of 1933 and fully disclose any compensation.  Please view our full disclaimer/disclosure at

Disclosure: No Position